allergic diseases
Conditions
Interventions
observation group:Take levocetirizine hydrochloride oral solution, once a night, 1.25mg (2.5ml) each time, for 2 consecutive weeks
Sponsors
Beijing Children's Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
0.5 Years to 2 Years
Inclusion criteria
Inclusion criteria: 1.Age 6 months to 2 years old, gender is not limited; 2.Have one or more general symptoms of allergic rhinitis (two or more local symptoms such as nasal congestion, watery rhinorrhea, nasal itching, sneezing, etc.), and the symptoms persist or accumulate for more than 1 hour per day; It may be accompanied by eye symptoms such as tearing, itching and congestion, and signs of allergic rhinitis: pale nasal mucosa, edema, and watery nasal discharge; 3.Able to obtain the written consent of the guardian; 4.The guardian can write a diary on behalf of the children.
Exclusion criteria
Exclusion criteria: 1. Children who are allergic to or have a history of allergy to the components of levocetirizine hydrochloride preparations or piperazine derivatives such as oxocetirizine cyclozine; 2. Children with a history of drug allergy; 3. Children who are taking some banned drugs (systemic corticosteroids, antileukotrienes, nedoromic acid and other antihistamines, systemic antibiotics, and other drugs judged to affect the test); 4. If the breast-feeding mother has children who take antihistamines during the trial; 5. Children who have used systemic corticosteroids within 30 days before the start of the treatment period; 6. Children who are undergoing immunotherapy or scheduled to start immunotherapy during the clinical study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| adverse event;Allergic Rhinitis Symptom Score; | — |
Countries
China
Contacts
Public ContactZhang Jie
Beijing Children's Hospital, Capital Medical University
Outcome results
None listed